Ocrevus, Ocrevus 920 mg solution for injection, Ocrevus, Ocrelizumab
CN45320
Phase 2 small_molecule active
Quick answer
Ocrevus, Ocrevus 920 mg solution for injection, Ocrevus, Ocrelizumab for Multiple Sclerosis (MS) is a Phase 2 program (small_molecule) at Roche Registration Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Roche Registration Limited
- Indication
- Multiple Sclerosis (MS)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active